Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mingyuan Medicare Buys Diagnostic Company for $55 Million

publication date: Aug 9, 2011
Mingyuan Medicare Development, a Hong Kong company that operates in the PRC, has agreed to buy a 70% stake in 18-month-old Shanghai Yuanqi for 354 million RMB ($55 million). Both companies provide cancer screening kits to the PRC. Shanghai Yuanqi has developed molecular diagnostic kits for leukemia, lymphoma, and individualized cancer therapy. Minyuan’s best selling product is its C-12 protein chip, which tests blood samples for 12 tumor markers that detect 12 types of cancer. More details....

Stock Symbol: (HK: 00233)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here